Sangamo BioSciences Company Description
Sangamo BioSciences hopes zinc fingers have the Midas touch when it comes to regulating gene expression. The company's zinc finger DNA-binding proteins (ZFPs) control gene expression (activation) and cell function; the firm aims to develop gene-correcting therapeutics for a variety of indications, including cancer, neurological conditions, infectious diseases, and cardiovascular disease. Its lead candidate SB-509 is in clinical trials as a treatment for diabetic neuropathy, and the company is also evaluating it as a treatment for Lou Gehrig's disease and peripheral artery disease. Other ZFP development programs include research in the areas of HIV, brain cancer, stroke, and spinal cord injury.
View the Comprehensive Company Description for Sangamo BioSciences
The Company Description provides a historical perspective of Sangamo BioSciences's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Sangamo BioSciences's evolution in the marketplace.
